Tag: Antifungals

Down the Pipeline: Rezafungin, the Once-per-Week Echinocandin

Echinocandins. This is the drug we use mostly on the inpatient side for invasive candidiasis. The most well known is micafungin, but analdafungin is another option that is also commonly used. Besides resistance, the issue with echinocandins are the fact they are intravenous drugs, which makes administration of it easy on the inpatient side but

Continue reading

The Terrifying Threat of Mucormycosis

If I had to name an infection that gives people nightmares, besides COVID as of the time of writing this, would be Mucormycosis. These are moulds of the order Mucorales, which are comprised of multiple species, including Rhizopus spp, Mucor spp, and Lichtheimia spp (formerly of the genera Absidia and Mycocladus). Others include Rhizomucor spp,

Continue reading

Kullberg, Bart Jan, et al. “Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: the ACTIVE Trial.” Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 68, no. 12, 2019, pp. 1981-1989.

The ACTIVE trial! This is a phase III, RCT, double blind, multicenter, non-inferiority trial comparing isavuconazole vs caspofungin in invasive candidiasis. Folks, in ID, it doesn’t get any better than this (look at all these studies!) Exclusion criteria were Candida in any body part (i.e. osteomyelitis, IE, meningitis), severe immunodeficiency, >48hrs of other antifungal therapy.

Continue reading